316 related articles for article (PubMed ID: 28507801)
1. The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?
Böger C; Behrens HM; Krüger S; Röcken C
Oncoimmunology; 2017; 6(4):e1293215. PubMed ID: 28507801
[TBL] [Abstract][Full Text] [Related]
2. Therapy Resistance in Neoadjuvantly Treated Gastric Cancer and Cancer of the Gastroesophageal Junction is Associated with an Increased Expression of Immune Checkpoint Inhibitors-Comparison Against a Therapy Naïve Cohort.
Schoop H; Bregenzer A; Halske C; Behrens HM; Krüger S; Egberts JH; Röcken C
Transl Oncol; 2020 Feb; 13(2):165-176. PubMed ID: 31865179
[TBL] [Abstract][Full Text] [Related]
3. The Transcriptomic Landscape of Gastric Cancer: Insights into Epstein-Barr Virus Infected and Microsatellite Unstable Tumors.
Gullo I; Carvalho J; Martins D; Lemos D; Monteiro AR; Ferreira M; Das K; Tan P; Oliveira C; Carneiro F; Oliveira P
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30018250
[TBL] [Abstract][Full Text] [Related]
4. Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers.
Derks S; Liao X; Chiaravalli AM; Xu X; Camargo MC; Solcia E; Sessa F; Fleitas T; Freeman GJ; Rodig SJ; Rabkin CS; Bass AJ
Oncotarget; 2016 May; 7(22):32925-32. PubMed ID: 27147580
[TBL] [Abstract][Full Text] [Related]
5. Blockade of V-domain immunoglobulin suppressor of T-cell activation reprograms tumour-associated macrophages and improves efficacy of PD-1 inhibitor in gastric cancer.
Cao Y; Yu K; Zhang Z; Gu Y; Gu Y; Li W; Zhang W; Shen Z; Xu J; Qin J
Clin Transl Med; 2024 Feb; 14(2):e1578. PubMed ID: 38356419
[TBL] [Abstract][Full Text] [Related]
6. The Expression Pattern and Clinical Significance of the Immune Checkpoint Regulator VISTA in Human Breast Cancer.
Xie X; Zhang J; Shi Z; Liu W; Hu X; Qie C; Chen W; Wang Y; Wang L; Jiang J; Liu J
Front Immunol; 2020; 11():563044. PubMed ID: 33250890
[TBL] [Abstract][Full Text] [Related]
7. Combined Assessment of Immune Checkpoint Regulator VISTA on Tumor-Associated Immune Cells and Platelet-to-Lymphocyte Ratio Identifies Advanced Germ Cell Tumors with Higher Risk of Unfavorable Outcomes.
Pęksa R; Kunc M; Popęda M; Piątek M; Bieńkowski M; Żok J; Starzyńska A; Perdyan A; Sowa M; Duchnowska R; Biernat W
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33916925
[TBL] [Abstract][Full Text] [Related]
8. Decreased Expression of Negative Immune Checkpoint VISTA by CD4+ T Cells Facilitates T Helper 1, T Helper 17, and T Follicular Helper Lineage Differentiation in GCA.
Hid Cadena R; Reitsema RD; Huitema MG; van Sleen Y; van der Geest KSM; Heeringa P; Boots AMH; Abdulahad WH; Brouwer E
Front Immunol; 2019; 10():1638. PubMed ID: 31379838
[TBL] [Abstract][Full Text] [Related]
9. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.
Kondo Y; Ohno T; Nishii N; Harada K; Yagita H; Azuma M
Oral Oncol; 2016 Jun; 57():54-60. PubMed ID: 27208845
[TBL] [Abstract][Full Text] [Related]
10. Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability.
Ma C; Patel K; Singhi AD; Ren B; Zhu B; Shaikh F; Sun W
Am J Surg Pathol; 2016 Nov; 40(11):1496-1506. PubMed ID: 27465786
[TBL] [Abstract][Full Text] [Related]
11. VISTA is an immune checkpoint molecule for human T cells.
Lines JL; Pantazi E; Mak J; Sempere LF; Wang L; O'Connell S; Ceeraz S; Suriawinata AA; Yan S; Ernstoff MS; Noelle R
Cancer Res; 2014 Apr; 74(7):1924-32. PubMed ID: 24691993
[TBL] [Abstract][Full Text] [Related]
12. New insights into the inflamed tumor immune microenvironment of gastric cancer with lymphoid stroma: from morphology and digital analysis to gene expression.
Gullo I; Oliveira P; Athelogou M; Gonçalves G; Pinto ML; Carvalho J; Valente A; Pinheiro H; Andrade S; Almeida GM; Huss R; Das K; Tan P; Machado JC; Oliveira C; Carneiro F
Gastric Cancer; 2019 Jan; 22(1):77-90. PubMed ID: 29779068
[TBL] [Abstract][Full Text] [Related]
13. VISTA: A Promising Target for Cancer Immunotherapy?
Tagliamento M; Agostinetto E; Borea R; Brandão M; Poggio F; Addeo A; Lambertini M
Immunotargets Ther; 2021; 10():185-200. PubMed ID: 34189130
[TBL] [Abstract][Full Text] [Related]
14. Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer.
Kok VC
Front Oncol; 2020; 10():268. PubMed ID: 32185135
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer.
Pereira MA; Ramos MFKP; Faraj SF; Dias AR; Yagi OK; Zilberstein B; Cecconello I; Alves VAF; de Mello ES; Ribeiro U
J Surg Oncol; 2018 Apr; 117(5):829-839. PubMed ID: 29534305
[TBL] [Abstract][Full Text] [Related]
16. VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML.
Wang L; Jia B; Claxton DF; Ehmann WC; Rybka WB; Mineishi S; Naik S; Khawaja MR; Sivik J; Han J; Hohl RJ; Zheng H
Oncoimmunology; 2018; 7(9):e1469594. PubMed ID: 30228937
[TBL] [Abstract][Full Text] [Related]
17. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
[TBL] [Abstract][Full Text] [Related]
18. Vista of the Future: Novel Immunotherapy Based on the Human V-Set Immunoregulatory Receptor for Digestive System Tumors.
Chmiel P; Gęca K; Michalski A; Kłosińska M; Kaczyńska A; Polkowski WP; Pelc Z; Skórzewska M
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373091
[TBL] [Abstract][Full Text] [Related]
19. New emerging targets in cancer immunotherapy: the role of VISTA.
Tagliamento M; Bironzo P; Novello S
ESMO Open; 2020 Jun; 4(Suppl 3):e000683. PubMed ID: 32554470
[TBL] [Abstract][Full Text] [Related]
20. Expression of V-domain immunoglobulin suppressor of T cell activation is associated with the advanced stage and presence of lymph node metastasis in ovarian cancer.
Liao H; Zhu H; Liu S; Wang H
Oncol Lett; 2018 Sep; 16(3):3465-3472. PubMed ID: 30127950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
